August 2022
-
08.03.2022 Research Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated Cardiomyopathy
July 2022
-
07.27.2022 Covid-19 Vaccines Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design -
07.19.2022 Covid-19 Vaccines Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate -
07.13.2022 Medicines Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion, USP (containing benzyl alcohol), Due To The Potential Presence of Visible Particulate. -
07.08.2022 Vaccines Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age -
07.08.2022 Vaccines Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®
June 2022
-
06.30.2022 Responsibility Pfizer Announces Commitment to Accelerate Climate Action and Achieve Net-Zero Standard by 2040 -
06.22.2022 Responsibility Statement by Pfizer Chairman and CEO Albert Bourla to Pfizer Colleagues -
06.15.2022 Vaccines Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine -
06.13.2022 Partnerships Research Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 -
06.05.2022 Partnerships Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory Multiple Myeloma